AlzeCure Pharma AB (publ) announced that an abstract with preclinical data on NeuroRestore ACD856 demonstrating its potential disease- modifying effects has been accepted for presentation at the annual Alzheimer's conference CTAD, Clinical Trials in Alzheimer's Disease, which this year is being held in Boston on October 24-27. The abstract, titled NeuroRestore ACD856, a Trk-PAM in clinical development for Alzheimer's disease shows neuroprotective and neurorestorative effects, will be presented at the international Alzheimer conference CTAD 2023 by Martin Jönsson, CEO at AlzeCure. Other authors are Pontus Forsell, Veronica Lidell, Azita Rasti, Gunnar Nordvall and Johan Sandin.

The presentation includes new preclinical results with ACD856, the lead candidate drug within the NeuroRestore platform. The data show that the substance exhibits both protective and regenerative effects on nerve cells, indicating potentially disease-modifying properties of this class of molecules. Previous preclinical studies have shown that AlzeCure's drug candidates strengthen communication between nerve cells and improve cognitive ability, including learning and memory functions.

ACD856 has undergone phase I clinical studies, where both good safety and tolerability were demonstrated in humans, but also that the candidate drug crossed the blood-brain barrier and that the substance activated parts of the brain that are central to both cognition and depression treatment.